Authorization

Nevro to Highlight Substantial Body of Clinical Evidence Supporting Expanded Applications and Unique Capabilities of HF10 Therapy at the 14th International Neuromodulation Society World Congress

SYDNEY, May 26, 2019 /PRNewswire/ --ANevro Corp.A(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the Company's HF10a?? therapy for patients with chronic pain.A Results will be presented at the International Neuromodulation Society (INS) meeting being held this week in Sydney, Australia. This year, 26 abstracts on HF10 therapy will be presented at INS, including ten prospective studies; ten retrospective studies; one clinical study design presentation, and five mechanism of action studies. AEight of the prospective studies and four of the retrospective studies will also be presented on the podium. AThe broad range of research investigates both new and established pain areas, programming techniques with HF10 therapy, and preclinical studies to understand the unique mechanism of action with HF10 therapy. "Nevro is committed to expanding the field of neuromodulation with our growing body of clinical evidence that supports the use of HF10 therapy," said D. Keith Grossman, Chairman, CEO and President of Nevro.A "The results of these studies demonstrate that our best-in-class therapy can significantly improve the lives of patients suffering from various forms of debilitating chronic pain."Details of the presentations and schedule (dates/times AEST) include:Monday, May 27, 2019A
16:50-17:00AAAAAAAA A Prospective Clinical Trial to Assess High Frequency Spinal Cord Stimulation (HF-SCS) at 10 kHz in the Treatment of Chronic Intractable Pain from Peripheral Polyneuropathy
Vincent Galan, MD17:00-17:10AAAAAAAA Spinal Cord Stimulation at 10 kHz for the Treatment of Chronic Focal Neuropathic Post-Surgical PainAAAAAAAAAAAAAAA
Mayank Gupta, MD17:10-17:20AAAAAAAA Spinal Cord Stimulation at 10 kHz for the Treatment of Chronic Pain of the Upper Extremities: Results of a Prospective, Multicenter, Post-Market, Observational StudyAAAAAAAAAAAAA
Kasra Amirdelfan, MD17:30-17:40AAAAAAAA High frequency spinal cord stimulation (HF-SCS) at 10 kHz for the treatment of chronic pain resulting from spinal cord injuryAA
Professor Sam Eldabe, MDTuesday, May 28, 2019
17:00-17:10AAAAAAAA Effects of Spinal Cord Stimulation on Chronic Refractory Painful Gastroparesis: A Retrospective Case Series AnalysisA
Leonardo Kapural, MD PhD17:10-17:20AAAAAAAA Treatment of chronic abdominal pain with 10 KHz Spinal Cord Stimulation:A Efficacy results from a 12 month prospective, multicenter, feasibility study in a series of patients with diverse pain etiologiesAAAAAAAA
Leonardo Kapural, MD, PhD17:40-17:50AAAAAAAA Pulse Dosing of 10 kHz Paresthesia-Independent Spinal Cord Stimulation Provides Same Efficacy with Substantial Reduction of Device Recharge Time
Mayank Gupta, MD18:10-18:20AAAAAAAA Prospective, Open Label, Pilot Study: One Year Results Of 10kHz Spinal Cord Stimulation (SCS) For Neuropathic Back Pain in Non-Operated Patients: The Maiden-Back StudyAAAAAAAAAA
Dr. Ganesan Baranidharan, MBBSWednesday, May 29, 2019
8:30-9:00AAAAAAAAAAAAA Prospective 12 Month Outcomes of Multi-Center Trials of 10 kHz Spinal Cord Stimulation in the Treatment of Arm and Neck Pain (Australian & North American Centers)AAAAAAAAAAAAA
Kasra Amirdelfan, MD and Dr. Paul Verrills, MBBS17:10-17:20AAAAAAAA Spinal Cord Stimulation at 10 kHz For Chronic Intractable Leg Pain: Australian Experience
Dr. Richard Sullivan, MBChB17:20-17:30AAAAAAAA Spinal Cord Stimulation at 10 kHz for Treatment of Chronic Head PainAAAAA
Dr. John Salmon, MBBS17:50-18:00AAAAAAAA Electropsychophysical Characterization of High-kHz Epidural Spinal Cord Stimulation
Dr. Paul Verrills, MBBSClinical Posters
A Prospective, Multi-Site, Clinical Trial of the Senzaa?? Spinal Cord Stimulation (SCS) System in the Treatment of Chronic Pelvic PainAAAAAAAAA
Sean Li, MDHigh Frequency Spinal Cord Stimulation at 10 kHz for the Treatment of Focal, Chronic, Post-Surgical Neuropathic PainAAAAAAAAAAAAAAA
Dr. Bart BilletHigh Frequency Spinal Cord Stimulation (HF-SCS) at 10 kHz for the Treatment of Neuropathic Limb Pain from Painful Diabetic NeuropathyAAAAA
Charles Argoff, MDA Multicenter Real-World Review of 10 kHz Spinal Cord Stimulation Outcomes for the Treatment of Chronic Trunk and/or Limb Pain in USAAAAAAAAAAAAAAA
Dawood Sayed, MDSpinal Cord Stimulation at 10 kHz for Treatment of Elhers Danlos SyndromeAAAAAAAA
Dr. John Salmon, MBBSCluneal Nerve Stimulation at 10 kHz for the Treatment of Chronic Neuropathic PainAAAAAAAA
Dr. Peter Courtney, MBBSImproved Chronic Widespread Pain and Motor Function using High Frequency Spinal Cord Stimulation (HF-SCS) at 10 kHz: A Case StudyAAAAAAAAAAA
Dr. Vahid Mohabbati, MBBSSpinal Cord Stimulation at 10 kHz for Chronic Intractable Pain: A Prospective Case Series in a Real-World Community PracticeAAAAAAAAAAAAAAA
Dr. Geoff Speldewinde, MBBSSpinal Cord Stimulation at 10 kHz for Treatment of Chronic Pain in a Compensable SettingAAAAAAAAAAAA
Dr. Gavin Weekes, MBBSPre-clinical and MoA Posters
10 kHz Electrical Stimulation of the Spinal Cord Suppresses Laser-Evoked Afferent Neural Hyperactivity
Zack Kagan, Ph.DComparing the Firing Patterns of Superficial Dorsal Horn Neurons Evoked by Robotically Automated and Human Manual Brushing and Von Frey Hair Stimulation
Dongchul Lee, Ph.DElectrical Activity Evoked by 10 kHz Spinal Cord Stimulation on Superficial Dorsal Horn Neurons in Neuropathic Pain RatsAAAAAA
Dongchul Lee, Ph.DDifferential modulation of spinal dorsal horn neurons by various spinal cord stimulation strategies
Kwan Lee, Ph.DHigh Frequency kHz Spinal Cord Stimulation (SCS) Modulate Spinal Dorsal Horn Neurons in Neuropathic Pain RatsAAAAAAAAAAAAAAA
Kwan Lee, Ph.DAbout Nevro Corp.A
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SenzaA System and Senza IIa?? System are the only SCS systems that deliver Nevro's proprietary HF10A therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.Investor Relations:
Juliet Cunningham
Vice President, Investor Relations
ir@nevro.com
Nevro to Highlight Substantial Body of Clinical Evidence Supporting Expanded Applications and Unique Capabilities of HF10 Therapy at the 14th International Neuromodulation Society World Congress
Nevro to Highlight Substantial Body of Clinical Evidence Supporting Expanded Applications and Unique Capabilities of HF10 Therapy at the 14th International Neuromodulation Society World Congress
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-to-highlight-substantial-body-of-clinical-evidence-supporting-expanded-applications-and-unique-capabilities-of-hf10-therapy-at-the-14th-international-neuromodulation-society-world-congress-300856892.htmlSOURCE Nevro Corp.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«     2020    »
 12345
6789101112
13141516171819
20212223242526
2728293031